A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

BACKGROUND: Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT(1A)) receptors in phase III clinical development for the treatment of schizophrenia. OBJECTIVE: This study aimed to investigate the effect of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukada, Hironobu, Chen, Yu-Luan, Xiao, Guangqing, Lennek, Lisa, Milanovic, Snezana M., Worden, MaryAlice, Polhamus, Daniel G., Chiu, Yu-Yuan, Hopkins, Seth C., Galluppi, Gerald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684410/
https://www.ncbi.nlm.nih.gov/pubmed/37882999
http://dx.doi.org/10.1007/s40262-023-01317-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684410/
https://www.ncbi.nlm.nih.gov/pubmed/37882999
http://dx.doi.org/10.1007/s40262-023-01317-4

Ejemplares similares